How AI can power GLP-1’s next frontier in medicine
Given growing access to data and advancements with AI, providers should be able to predict which patients will fare better on a specific weight loss drug.
Originally developed to treat diabetes, GLP-1 agonists—now also popularly known as obesity drugs—have been making headlines for their weight-loss effects. Now, the commercial success of these GLP-1s such as Ozempic, Wegovy, Mounjaro, and Zepbound has unlocked a flurry of new research into how this blockbuster drug class may support more treatments beyond just diabetes and weight loss.
Welcome to Billionaire Club Co LLC, your gateway to a brand-new social media experience! Sign up today and dive into over 10,000 fresh daily articles and videos curated just for your enjoyment. Enjoy the ad free experience, unlimited content interactions, and get that coveted blue check verification—all for just $1 a month!
Account Frozen
Your account is frozen. You can still view content but cannot interact with it.
Please go to your settings to update your account status.
Open Profile Settings